Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04315701 · ClinicalTrials.gov registry record · Phase 2
A PD-1 Checkpoint Inhibitor (Cemiplimab) for High-Risk Localized, Locally Recurrent, or Regionally Advanced Skin Cancer
A Phase 2 study of Recurrent Skin Squamous Cell Carcinoma and Resectable Skin Squamous Cell Carcinoma, sponsored by University of Southern California.
- Active
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 5
- Study locations
NCT04315701 is a Phase 2 study of Recurrent Skin Squamous Cell Carcinoma and Resectable Skin Squamous Cell Carcinoma that is active but no longer recruiting, run by University of Southern California. The registered enrollment target is 35 participants. The trial reports 5 study locations across 3 states.
The verdict
NCT04315701, a Phase 2 study of Recurrent Skin Squamous Cell Carcinoma and Resectable Skin Squamous Cell Carcinoma, is active but no longer recruiting, sponsored by University of Southern California.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 5
- Study locations
Study Summary
This phase II trial studies how well cemiplimab before surgery works in treating patients with skin cancer that is high-risk and has not spread to other parts of the body (localized), has come back locally (locally recurrent), or has spread regionally (regionally advanced), and can be removed by surgery (resectable). Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Conditions Studied
Interventions
- BIOLOGICAL Cemiplimab
- PROCEDURE Resection
Study Locations (5)
California
- Los Angeles County-USC Medical Center - Los Angeles
- USC / Norris Comprehensive Cancer Center - Los Angeles
- Hoag Memorial Hospital - Newport Beach
Illinois
- Northwestern University Feinberg School of Medicine - Chicago
Nebraska
- University of Nebraska - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2020-06-17 |
| Est. Completion | 2027-06-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04315701
The ClinicalTrials.gov registry entry for NCT04315701 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Recurrent Skin Squamous Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Cemiplimab is the first listed.
NCT04315701 reports 5 study locations spanning 3 distinct geographic areas - top geographies include California, Illinois, Nebraska.
Frequently Asked Questions
What is clinical trial NCT04315701 about?
NCT04315701 is a clinical study titled "A PD-1 Checkpoint Inhibitor (Cemiplimab) for High-Risk Localized, Locally Recurrent, or Regionally Advanced Skin Cancer". This phase II trial studies how well cemiplimab before surgery works in treating patients with skin cancer that is high-risk and has not spread to other parts of the body (localized), has come back locally (locally recurrent), or has spread regionally (regionally advanced), and can be removed by sur...
What is the current status of trial NCT04315701?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2020-06-17. Estimated completion is 2027-06-17.
What conditions does trial NCT04315701 study?
This clinical trial studies the following conditions: Recurrent Skin Squamous Cell Carcinoma, Resectable Skin Squamous Cell Carcinoma, Stage I Skin Cancer, Stage II Skin Cancer, Stage III Skin Cancer.
What interventions are being tested in trial NCT04315701?
The interventions under investigation include: Cemiplimab (BIOLOGICAL), Resection (PROCEDURE).
Who is sponsoring clinical trial NCT04315701?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04315701 being conducted?
This trial has 5 study locations across California, Illinois, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Skin Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Recurrent Skin Squamous Cell Carcinoma
All registered trials for this condition
Resectable Skin Squamous Cell Carcinoma
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.